Literature DB >> 14999732

Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model.

Vijay K Gombar1, Joseph W Polli, Joan E Humphreys, Stephen A Wring, Cosette S Serabjit-Singh.   

Abstract

A quantitative structure-activity relationship (QSAR) model has been developed to predict whether a given compound is a P-glycoprotein (Pgp) substrate or not. The training set consisted of 95 compounds classified as substrates or non-substrates based on the results from in vitro monolayer efflux assays. The two-group linear discriminant model uses 27 statistically significant, information-rich structure quantifiers to compute the probability of a given structure to be a Pgp substrate. Analysis of the descriptors revealed that the ability to partition into membranes, molecular bulk, and the counts and electrotopological values of certain isolated and bonded hydrides are important structural attributes of substrates. The model fits the data with sensitivity of 100% and specificity of 90.6% in the jackknifed cross-validation test. A prediction accuracy of 86.2% was obtained on a test set of 58 compounds. Examination of the eight "mispredicted" compounds revealed two distinct categories. Five mispredictions were explained by experimental limitations of the efflux assay; these compounds had high permeability and/or were inhibitors of calcein-AM transport. Three mispredictions were due to limitations of the chemical space covered by the current model. The Pgp QSAR model provides an in silico screen to aid in compound selection and in vitro efflux assay prioritization. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999732     DOI: 10.1002/jps.20035

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  20 in total

Review 1.  Positron emission tomography molecular imaging for drug development.

Authors:  Paul M Matthews; Eugenii A Rabiner; Jan Passchier; Roger N Gunn
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 2.  Recent progress in the computational prediction of aqueous solubility and absorption.

Authors:  Stephen R Johnson; Weifan Zheng
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 3.  Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

Authors:  Mohammad S Alavijeh; Mansoor Chishty; M Zeeshan Qaiser; Alan M Palmer
Journal:  NeuroRx       Date:  2005-10

Review 4.  On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the "space-time" dimension of MDR.

Authors:  Vasiliki Panagiotopoulou; Giles Richardson; Oliver E Jensen; Cyril Rauch
Journal:  Eur Biophys J       Date:  2009-11-04       Impact factor: 1.733

Review 5.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

6.  Boosted feature selectors: a case study on prediction P-gp inhibitors and substrates.

Authors:  Gonzalo Cerruela García; Nicolás García-Pedrajas
Journal:  J Comput Aided Mol Des       Date:  2018-10-26       Impact factor: 3.686

7.  Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis.

Authors:  Niveditha Muralidharan; Paul T Antony; Vikramraj K Jain; Christina Mary Mariaselvam; Vir Singh Negi
Journal:  Eur J Clin Pharmacol       Date:  2015-06-14       Impact factor: 2.953

Review 8.  The significance of acid/base properties in drug discovery.

Authors:  David T Manallack; Richard J Prankerd; Elizabeth Yuriev; Tudor I Oprea; David K Chalmers
Journal:  Chem Soc Rev       Date:  2013-01-21       Impact factor: 54.564

Review 9.  Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).

Authors:  Yash A Gandhi; Marilyn E Morris
Journal:  AAPS J       Date:  2009-07-24       Impact factor: 4.009

10.  Discovery of novel antitumor antimitotic agents that also reverse tumor resistance.

Authors:  Aleem Gangjee; Jianming Yu; Jean E Copper; Charles D Smith
Journal:  J Med Chem       Date:  2007-06-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.